Format

Send to

Choose Destination
Gynecol Endocrinol. 2018 Jul;34(7):545-550. doi: 10.1080/09513590.2017.1421632. Epub 2018 Jan 8.

The use of inositol(s) isomers in the management of polycystic ovary syndrome: a comprehensive review.

Author information

1
a Clinic of Endocrinology , Alexandrovska University Hospital, Medical University , Sofia , Bulgaria.
2
b Health Department , UniPoliSi - Institut des Etudes Universitaires , Disentis , Switzerland.

Abstract

The aim of this review is to present the current data about the role of inositols in the management of polycystic ovary syndrome (PCOS) women and in the prevention and treatment of gestational diabetes mellitus (GDM). We analyzed the available literature with key words PCOS, Myo-inositol, D-chiro-inositol, assisted reproductive technologies and GDM. The most recent literature would suggest that Myo-inositol, D-chiro-inositol and their combination in physiological ratio 40:1 could represent an important therapeutic strategy for the improvement of metabolic, hormonal and reproductive aspects of PCOS. In assisted reproductive technologies, however, myo-inositol and the combined treatment, despite D-chiro-inositol monotherapy, are able to improve clinical outcomes. Myo-inositol monotherapy results more effective in preventing and treating GDM even if a larger cohort of studies is needed to better clarify these results.

KEYWORDS:

D-chiro-inositol; GDM; PCOS; assisted reproductive techniques; myo-inositol

PMID:
29309199
DOI:
10.1080/09513590.2017.1421632
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center